Document is current
Any future updates will be listed below
-
Authors
Spichiger, Frank
Volken, Thomas
Bosshard, Georg
Zigan, Nicole
Blanc, Geneviève
Büscher, Andreas
Nagl-Cupal, Martin
Bernard, Mathieu
Rubli Truchard, Eve
Larkin, Philip
Koppitz, Andrea
-
Funding
Funding for this research was provided by:
Swiss Federal Office of Public Health
Schweizerische Akademie der Medizinischen Wissenschaften (2015/14)
Stanley Thomas Johnson Stiftung,Switzerland (2015/14)
Alzheimer Schweiz
Ebnet-Stiftung
- License Information
-
More Information
Article History
Received: 15 June 2022
Accepted: 6 December 2022
First Online: 29 December 2022
Declarations
:
: All participants are requested to provide informed consent and sign a consent form for participation before data collection. The consent form, and study material have been approved by both relevant Swiss regional Ethics Committees of the Canton of Zürich (01-2016, 2016) and Canton of Thurgau (K2016/02). The trial has been approved by the Swiss regional Ethics Committee of the Canton of Zürich (03/28/2019) as the leading Ethics Committee for the two regions, with clearance certification number ZH BASEC 2016-0001. The trial was planned and undertaken according to the European Medicines Agency good clinical practice guidelines [CitationRef removed] which are based upon the declaration of Helsinki [CitationRef removed].
: All participants provided informed consent for publication via informed consent form for publication before data collection.
: All authors confirm they have no conflicts of interest to disclose.
